Literature DB >> 16007269

What about Th1/Th2 in cutaneous leishmaniasis vaccine discovery?

A Campos-Neto1.   

Abstract

The T helper cell type 1 (Th1) response is essential to resist leishmaniasis, whereas the Th2 response favors the disease. However, many leishmanial antigens, which stimulate a Th1 immune response during the disease or even after the disease is cured, have been shown to have no protective action. Paradoxically, antigens associated with an early Th2 response have been found to be highly protective if the Th1 response to them is generated before infection. Therefore, finding disease-associated Th2 antigens and inducing a Th1 immune response to them using defined vaccination protocols is an interesting unorthodox alternative approach to the discovery of a leishmania vaccine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16007269     DOI: 10.1590/s0100-879x2005000700001

Source DB:  PubMed          Journal:  Braz J Med Biol Res        ISSN: 0100-879X            Impact factor:   2.590


  16 in total

1.  T-cell expression cloning of Porphyromonas gingivalis genes coding for T helper-biased immune responses during infection.

Authors:  Reginaldo B Gonçalves; Onir Leshem; Karen Bernards; John R Webb; Philip P Stashenko; Antonio Campos-Neto
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

2.  Immune responses in DNA vaccine formulated with PMMA following immunization and after challenge with Leishmania major.

Authors:  Somayeh Zarrati; Mehdi Mahdavi; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-08-31

3.  The role of Montanide ISA 70 as an adjuvant in immune responses against Leishmania major induced by thiol-specific antioxidant-based protein vaccine.

Authors:  Narges Khabazzadeh Tehrani; Mehdi Mahdavi; Fatemeh Maleki; Somayeh Zarrati; Fatemeh Tabatabaie
Journal:  J Parasit Dis       Date:  2014-09-20

4.  Th1 biased response to a novel Porphyromonas gingivalis protein aggravates bone resorption caused by this oral pathogen.

Authors:  Onir Leshem; Suely S Kashino; Reginaldo B Gonçalves; Noriyuki Suzuki; Masao Onodera; Akira Fujimura; Hajime Sasaki; Philip Stashenko; Antonio Campos-Neto
Journal:  Microbes Infect       Date:  2008-03-25       Impact factor: 2.700

5.  Contrasting human cytokine responses to promastigote whole-cell extract and the Leishmania analogue receptor for activated C kinase antigen of L. amazonensis in natural infection versus immunization.

Authors:  R B G Azeredo-Coutinho; D C S Matos; G G R Armôa; R M Maia; A Schubach; W Mayrink; S C F Mendonça
Journal:  Clin Exp Immunol       Date:  2008-07-08       Impact factor: 4.330

6.  The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the Leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers.

Authors:  S Iborra; D R Abánades; N Parody; J Carrión; R M Risueño; M A Pineda; P Bonay; C Alonso; M Soto
Journal:  Clin Exp Immunol       Date:  2007-09-27       Impact factor: 4.330

Review 7.  Potential biomarkers of immune protection in human leishmaniasis.

Authors:  Mahmoud Nateghi Rostami; Ali Khamesipour
Journal:  Med Microbiol Immunol       Date:  2021-05-02       Impact factor: 3.402

8.  Vaccines for the leishmaniases: proposals for a research agenda.

Authors:  Carlos Henrique Nery Costa; Nathan C Peters; Sandra Regina Maruyama; Eldo Cardoso de Brito; Isabel Kinney Ferreira de Miranda Santos
Journal:  PLoS Negl Trop Dis       Date:  2011-03-29

9.  Leishmania donovani whole cell antigen delivered with adjuvants protects against visceral leishmaniasis in vervet monkeys (Chlorocebus aethiops).

Authors:  Joshua Muli Mutiso; John Chege Macharia; Evans Taracha; Michael Muita Gicheru
Journal:  J Biomed Res       Date:  2012-01

10.  Histopathological and immunohistochemical aspects of American cutaneous leishmaniasis before and after different treatments.

Authors:  Agostinho Gonçalves Viana; Wilson Mayrink; Carlos Alberto de Carvalho Fraga; Luciana Maria Silva; Patrícia Luciana Batista Domingos; Paulo Rogério Ferreti Bonan; Alfredo Maurício Batista de Paula; Ana Cristina de Carvalho Botelho
Journal:  An Bras Dermatol       Date:  2013 Jan-Feb       Impact factor: 1.896

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.